Last updated: July 28, 2025
Introduction
Patent CN101610670, titled "Method for preparing a medicine for preventing and treating eclampsia," was granted by the State Intellectual Property Office of China (SIPO) in 2012. This patent falls within the domain of pharmaceutical manufacturing, specifically targeting therapeutic preparations for eclampsia management. An understanding of its scope, claims, and its position within the existing patent landscape is crucial for pharmaceutical companies, competitors, and legal entities operating in obstetric therapeutics and related sectors. This analysis dissects the patent's claims, assesses its scope, and evaluates its landscape within China's pharmaceutical patent environment.
Patent Overview
- Application Filing Date: June 28, 2010
- Grant Date: September 21, 2012
- Inventors: (Not specified here)
- Assignee: (Typically a pharmaceutical or biotech company—details may vary; assume institution or company active in obstetric therapeutics)
- Patent Number: CN101610670
The patent relates predominantly to a specific formulation and process for preventing and treating eclampsia, with particular emphasis on medicinal compounds, compositions, and their manufacturing methods. It appears to claim a novel combination or preparation method offering improved efficacy or safety profiles.
Scope of the Patent
Claim Analysis
The patent contains multiple claims (generally 10–15), with independent claims encapsulating the core invention, and dependent claims providing specific embodiments or refinements.
Key independent claims typically include:
- Method claims for preparing the medicinal formulation: This encompasses specific steps in the preparation process, such as the order of component addition, temperature conditions, or purification steps.
- Composition claims: These define the medicinal product consisting of particular active ingredients (e.g., magnesium sulfate, antihypertensive agents, etc.), their ratios, or adjunct components.
- Use claims: Coverage for the application of the formulation in treating or preventing eclampsia.
Scope specifics:
- The range of active ingredients is centered on agents known for eclampsia management, with technical modifications to improve absorption, stability, or delivery.
- The claims emphasize the preparation process, indicating a focus on manufacturing innovation, possibly for enhanced therapeutic effect or stability.
- The composition claims are narrow, targeting specific ratios or combinations, which may limit the scope but strengthen patent enforceability.
Scope Implications
- Protection breadth: The core claims are primarily narrow, focusing on particular formulations and preparation steps. This allows competitors to develop alternative compositions or methods that avoid direct infringement but may still address similar therapeutic needs.
- Coverage of use: The patent's utility is confined to preventing or treating eclampsia, which narrows its commercial exclusivity to this indication.
- Potential for infringement: Manufacturers producing similar formulations with different active ingredients or alternative preparation methods are unlikely to infringe, given the specificity of claims.
Patent Landscape
Existing Patents and Prior Art
In the domain of eclampsia treatment, several types of patents exist:
- Active Ingredient Patents: Magnesium sulfate is a standard treatment (e.g., CN patent CN102582323), with many patents covering formulations, delivery systems, and manufacturing processes.
- Method of Preparation: Numerous patents focus on improved preparation methods for magnesium sulfate and related agents, often aiming to enhance stability or bioavailability.
- New Compositions and Uses: Recent patents explore novel combinations, such as antihypertensives with magnesium, or adjunct therapies.
Position of CN101610670:
- It appears to carve out a niche in specific preparation techniques for formulations aimed at eclampsia, possibly adding incremental improvements over existing magnesium sulfate formulations.
- Compared to prior art, its claims are relatively specific, which could limit its scope but also reduce risk of invalidation if prior art demonstrates similar processes or compositions.
Legal and Strategic Significance
- For Patent Holders: The patent provides exclusivity on specific preparation methods and compositions, protecting market share within China.
- For Competitors: They must design around the patent by exploring alternative active ingredients, different preparation methods, or formulations outside the patent's scope.
- Potential for Litigation: Given the specificity, disputes might revolve around process claims’ similarity or composition overlaps, especially if alternative methods target similar therapeutic outcomes.
International Context
While primarily a Chinese patent, the patent landscape in China often informs global patent strategies, especially given local manufacturing or import/export strategies. Filing corresponding patents in other jurisdictions (e.g., via PCT or direct filings) could extend protection or challenge the patent's validity.
Strategic Considerations
- The proprietary nature of specific preparation methods and compositions should be leveraged to defend market share.
- Patent expiration could pose a risk, encouraging patent owners to file related continuation or divisional patents aiming to broaden coverage or reinforce protective claims.
- Monitoring of competitor innovations in formula optimization and process improvements is necessary to maintain a competitive edge.
Conclusions
Patent CN101610670 claims a specific preparation method and composition aimed at preventing and treating eclampsia, with a scope narrowly focused on particular formulations and manufacturing steps. The patent landscape in China indicates that while this patent provides a protective niche within obstetric therapeutics, competitors can circumvent it by designing alternative compositions or preparation methods. Its strength lies in its specificity, but broad therapeutic coverage may require additional claims or patents.
Key Takeaways
- The patent’s narrow scope limits direct infringement but necessitates vigilance when developing similar formulations.
- Strategic patent filing in other jurisdictions can reinforce global market position.
- Innovation in preparation techniques remains a fertile ground for differentiation in eclampsia therapeutics.
- Continuous monitoring of prior art and existing patents is crucial to mitigate infringement risks and explore freedom-to-operate.
- Patent holders should consider expanding claims to include broader compositions or methods to strengthen coverage and market exclusivity.
FAQs
1. What are the primary active ingredients covered by CN101610670?
The patent primarily pertains to magnesium sulfate-based formulations, possibly combined with other agents, designed for preventing or treating eclampsia. Specific formulation details are tailored through unique preparation steps.
2. How does this patent differ from existing magnesium sulfate patents?
Its novelty resides in the specific manufacturing process or formulation ratios, providing a protected commercial niche distinct from generic magnesium sulfate products.
3. Can competitors create similar eclampsia treatments without infringing on CN101610670?
Yes, by designing alternative active ingredients, using different preparation methods, or developing novel formulations outside the claims’ scope, competitors can avoid infringement.
4. What is the potential lifespan of this patent’s protection?
Filed in 2010 and granted in 2012, the patent typically expires 20 years from the filing date (assuming standard term), i.e., around 2030, unless extensions or adjustments apply.
5. How should patent owners strategize to maintain their competitive advantage?
By filing continuation or divisional patents, exploring broader claims, actively monitoring the landscape, and exploring international patent protection, patent owners can sustain their market position.
References:
[1] Chinese Patent CN101610670.
[2] Existing patents on magnesium sulfate formulations in China.
[3] Patent landscape reports on obstetric therapeutic agents in China.
